Vytorin on Carotid Intima-media Thickness and Overall Rigidity

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Cardiovascular Diseases
Interventions
DRUG

ezetimibe (+) simvastatin

Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets

DRUG

simvastatin

Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets

DRUG

pravastatin

Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Hospital Universitario 12 de Octubre

OTHER

NCT00738296 - Vytorin on Carotid Intima-media Thickness and Overall Rigidity | Biotech Hunter | Biotech Hunter